Elevated hematocrit is common in chronic smokers and has notable implications for perioperative management. Smoking-related secondary erythrocytosis develops primarily because chronic carbon monoxide exposure and intermittent hypoxemia stimulate erythropoietin production, increasing red blood cell mass. While this physiologic adaptation may improve oxygen-carrying capacity in chronically hypoxic patients, excessive hematocrit elevation can increase blood viscosity and contribute to perioperative thrombotic and cardiovascular complications.
In smokers, elevated hematocrit is often accompanied by endothelial dysfunction, platelet activation, chronic inflammation, and impaired oxygen delivery despite increased hemoglobin concentration. Carbon monoxide exposure shifts the oxyhemoglobin dissociation curve to the left, reducing tissue oxygen unloading. As a result, patients may exhibit relative tissue hypoxia even when pulse oximetry appears acceptable. These physiologic changes are particularly relevant during anesthesia because perioperative hemodynamic fluctuations can further compromise microvascular perfusion.
The perioperative evaluation of smokers with elevated hematocrit should focus on distinguishing secondary erythrocytosis from primary hematologic disorders such as polycythemia vera. A detailed smoking history, a review of thrombotic history, and an assessment for chronic obstructive pulmonary disease, obstructive sleep apnea, or chronic hypoxemia are essential to an adequate evaluation. Laboratory evaluation may include repeat hematocrit measurement, arterial blood gas analysis, erythropoietin level, and JAK2 mutation testing when clinically indicated. Mild elevations are common among smokers and may not require intervention, whereas hematocrit values exceeding 55% are generally associated with increased viscosity-related risk.
Smoking cessation remains the most effective long-term intervention. Even short-term abstinence before surgery can reduce carboxyhemoglobin levels and improve mucociliary function. Carbon monoxide levels decline substantially within 12 to 24 hours of smoking cessation, improving oxygen delivery during the perioperative period. Preoperative counseling should therefore encourage cessation whenever feasible, even if surgery is imminent.
Perioperative management strategies depend on the degree of hematocrit elevation and the patient’s comorbidities. Adequate hydration is particularly important because intravascular volume depletion can further increase viscosity. Intraoperative maintenance of euvolemia and avoidance of prolonged hypotension are critical to preserving tissue perfusion. Some clinicians recommend considering phlebotomy in symptomatic patients or those with markedly elevated hematocrit, particularly when values exceed 56% to 60%. However, routine preoperative phlebotomy for smoker-related erythrocytosis remains controversial because excessive reduction in red cell mass may impair oxygen transport in chronically hypoxemic individuals.
Anesthetic management should also address the elevated thrombotic risk associated with smoking and erythrocytosis. Mechanical venous thromboembolism prophylaxis should be implemented routinely, and pharmacologic prophylaxis may be indicated depending on surgical risk and patient-specific factors. Regional anesthesia may provide advantages through reduced sympathetic activation and earlier postoperative mobilization, although coagulation status and anticoagulation plans must be considered carefully.
Postoperatively, close monitoring for hypoxemia, myocardial ischemia, stroke, and venous thromboembolism is warranted. Pulmonary complications remain common in smokers, and aggressive pulmonary hygiene, early ambulation, and adequate analgesia are essential components of care. Ultimately, perioperative management of elevated hematocrit in smokers requires individualized assessment balancing viscosity-related risk against the patient’s underlying oxygenation needs. Anesthesiologists play a central role in optimizing these patients through careful preoperative evaluation, intraoperative hemodynamic management, and postoperative thromboprophylaxis.
References
- Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-351. https://pubmed.ncbi.nlm.nih.gov/1198126/
- Smith JR, Landaw SA. Smokers’ polycythemia. N Engl J Med. 1978;298(1):6-10. 10.1056/NEJM197801052980102
- Spivak JL. Polycythemia vera and other myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2003:40-58. 10.1056/NEJMra1406186
- Warner DO. Perioperative abstinence from cigarettes: physiologic and clinical consequences. Anesthesiology. 2006;104(2):356-367. 10.1097/00000542-200602000-00023
- Musallam KM, Tamim HM, Richards T, et al. Preoperative hematocrit levels and postoperative outcomes in noncardiac surgery: a retrospective cohort analysis. Lancet. 2011;378(9800):1396-1407. 10.1001/jama.297.22.2481




